Top-News
Professionelle Dienstleistungen Schweden

Calliditas Therapeutics AB News

Aktie
WKN:  A2JP36 ISIN:  SE0010441584 US-Symbol:  CLTEF
18,26 €
+0,04 €
+0,22%
04.06.24 14:28:02
Handeln Depot/Watchlist
Aktienanzahl *
59,58 Mio.
Marktkapitalisierung *
1,09 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 15.01.2024

Calliditas Therapeutics AB News

18.05.22 - PLX
Calliditas Q1 Operating Loss SEK 208.4 Million
(PLX AI) – Calliditas Q1 sales amounted to SEK 49.7 million, whereof TARPEYO net sales amounted to SEK 18.0 million. • Operating loss amounted to SEK 208.4 million and SEK ...
18.11.21 - PLX
Calliditas Posts Positive Operating Profit for the Third Quarter
(PLX AI) – Calliditas Q3 net sales amounted to SEK 198.2 million. • Q3 operating profit SEK 7.9 million • Q3 EPS SEK 0.21
16.09.21 - PLX
Caliditas Says MAA Review of Nefecon Delayed 3 Months in Europe
(PLX AI) – Calliditas Updated regulatory timeline for review of MAA in Europe. • European Medicine Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has decided to ...
16.09.21 - PLX
Calliditas Competitor Travere Outlicenses IgAN Therapy to Vifor Pharma
(PLX AI) – Calliditas competitor Travere signed a license agreement for its IgAN therapy, sparsentan, with Vifor Pharma. • Sparsentan is a potential first-​in-class treatment to address ...
14.09.21 - PLX
Calliditas Says FDA Extends PDUFA Goal Date for Nefecon to Dec. 15
(PLX AI) – Calliditas says U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for its New Drug Application (NDA) seeking accelerated approval for Nefecon ...
19.08.21 - PLX
Calliditas Q2 Operating Loss SEK 159.4 Million
(PLX AI) – Calliditas Q2 operating loss amounted to SEK 159.4 million. • No net sales were recognized for the three months ended June 30, 2021 and 2020, respectively • Loss before ...
12.08.21 - PLX
Calliditas to Sell Shares for SEK 300 Million
(PLX AI) – Calliditas to carry out a directed issue of common shares of approximately SEK 300 million to Swedish and international institutional investors. • The Company intends to ...
21.07.21 - PR Newswire
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe Calliditas and STADA partner to bring a specialty therapy ...
15.07.21 - PR Newswire
Calliditas secures $75 million term loan facility
Calliditas secures $75 million term loan facility PR Newswire
15.07.21 - PR Newswire
Calliditas secures $75 million term loan facility
Calliditas secures $75 million term loan facility PR Newswire
28.05.21 - PR Newswire
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency PR Newswire
28.05.21 - PR Newswire
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency PR Newswire
28.05.21 - PR Newswire
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference PR Newswire
28.05.21 - PR Newswire
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference PR Newswire
27.05.21 - PR Newswire
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire
27.05.21 - PR Newswire
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire
18.05.21 - PR Newswire
Interim Report Q1, 2021
Interim Report Q1, 2021 PR Newswire
18.05.21 - PR Newswire
Interim Report Q1, 2021
Interim Report Q1, 2021 PR Newswire
14.05.21 - PR Newswire
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021 PR Newswire
14.05.21 - PR Newswire
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021 PR Newswire

Newssuche

Videos

newspaper
29.05.24 -19,67%
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »